GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Blueberries Medical Corp (OTCPK:BBRRF) » Definitions » Debt-to-EBITDA

Blueberries Medical (Blueberries Medical) Debt-to-EBITDA : -2.06 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Blueberries Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Blueberries Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.07 Mil. Blueberries Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.11 Mil. Blueberries Medical's annualized EBITDA for the quarter that ended in Sep. 2023 was $-0.58 Mil. Blueberries Medical's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -2.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Blueberries Medical's Debt-to-EBITDA or its related term are showing as below:

BBRRF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.14   Med: -0.36   Max: -0.08
Current: -2.14

During the past 10 years, the highest Debt-to-EBITDA Ratio of Blueberries Medical was -0.08. The lowest was -2.14. And the median was -0.36.

BBRRF's Debt-to-EBITDA is ranked worse than
100% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.665 vs BBRRF: -2.14

Blueberries Medical Debt-to-EBITDA Historical Data

The historical data trend for Blueberries Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueberries Medical Debt-to-EBITDA Chart

Blueberries Medical Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.08 -0.36 -0.36 -1.65

Blueberries Medical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.83 2.83 -1.14 -1.11 -2.06

Competitive Comparison of Blueberries Medical's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Blueberries Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueberries Medical's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Blueberries Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Blueberries Medical's Debt-to-EBITDA falls into.



Blueberries Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Blueberries Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.881 + 0.102) / -0.597
=-1.65

Blueberries Medical's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.072 + 0.112) / -0.576
=-2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Blueberries Medical  (OTCPK:BBRRF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Blueberries Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Blueberries Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueberries Medical (Blueberries Medical) Business Description

Traded in Other Exchanges
Address
8500 West Georgia Street, Suite 2200, Vancouve, BC, CAN, V6C 3E8
Blueberries Medical Corp is a licensed producer of psychoactive and non-psychoactive cannabis by-products in Colombia. It cultivates, produces, and distributes cannabidiol (CBD) and THC (tetrahydrocannabinol) based medical cannabis domestically as well as internationally. It generates all of its revenues from Colombia.

Blueberries Medical (Blueberries Medical) Headlines

From GuruFocus

Blueberries Medical Reports Q1-2023

By sperokesalga sperokesalga 05-30-2023